Adverse Effects of Aromatase Inhibition on the Brain and Behavior in a Nonhuman Primate
Open Access
- 26 December 2018
- journal article
- research article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 39 (5) , 918-928
Abstract
Breast cancer patients using aromatase inhibitors (AIs) as an adjuvant therapy often report side effects, including hot flashes, mood changes, and cognitive impairment. Despite long-term use in humans, little is known about the effects of continuous AI administration on the brain and cognition. We used a primate model of human cognitive aging, the common marmoset, to examine the effects of a 4-week daily administration of the AI letrozole (20 μg, p.o.) on cognition, anxiety, thermoregulation, brain estrogen content, and hippocampal pyramidal cell physiology. Letrozole treatment was administered to both male and female marmosets and reduced peripheral levels of estradiol (E2), but unexpectedly increased E2 levels in the hippocampus. Spatial working memory and intrinsic excitability of hippocampal neurons were negatively affected by the treatment possibly due to increased hippocampal E2. While no changes in hypothalamic E2 were observed, thermoregulation was disrupted by letrozole in females only, indicating some impact on hypothalamic activity. These findings suggest adverse effects of AIs on the primate brain and call for new therapies that effectively prevent breast cancer recurrence while minimizing side effects that further compromise quality of life.SIGNIFICANCE STATEMENTAromatase inhibitors (AIs) are used as an adjuvant therapy for estrogen-receptor-positive breast cancer and are associated with side effects, including hot flashes, depression/anxiety, and memory deficits severe enough for many women to discontinue this life-saving treatment. AIs are also used by men, yet sex differences in the reported side effects have not been systematically studied. We show that AI-treated male and female marmosets exhibit behavioral changes consistent with these CNS symptoms, as well as elevated hippocampal estradiol and compromised hippocampal physiology. These findings illustrate the need for (1) a greater understanding of the precise mechanisms by which AIs impact brain function and (2) the development of new treatment approaches for breast cancer patients that minimize adverse effects on the brain.Keywords
This publication has 74 references indexed in Scilit:
- Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitorsSupportive Care in Cancer, 2012
- Estradiol synthesis within the human brainNeuroscience, 2011
- Ovarian Hormone Deficiency Reduces Intrinsic Excitability and Abolishes Acute Estrogen Sensitivity in Hippocampal CA1 Pyramidal NeuronsJournal of Neuroscience, 2011
- Modeling hot flushes and quality of life in breast cancer survivorsClimacteric, 2011
- Combined Liquid and Solid-Phase Extraction Improves Quantification of Brain Estrogen ContentFrontiers in Neuroanatomy, 2011
- Estradiol Acutely Potentiates Hippocampal Excitatory Synaptic Transmission through a Presynaptic MechanismThe Journal of Neuroscience, 2010
- Effects of Estradiol on the Thermoneutral Zone and Core Temperature in Ovariectomized RatsEndocrinology, 2010
- Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancerMenopause, 2007
- Performance of the marmoset monkey on computerized tasks of attention and working memoryCognitive Brain Research, 2004
- Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1European Journal of Cancer, 1999